These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

180 related items for PubMed ID: 22389951

  • 1. New dopamine agonist pramipexole improves parkinsonism and depression in Parkinson's disease.
    Harada T, Ishizaki F, Horie N, Nitta Y, Yamada T, Sasaki T, Nagakane T, Yasumatsu Y, Nitta K, Katsuoka H.
    Hiroshima J Med Sci; 2011 Dec; 60(4):79-82. PubMed ID: 22389951
    [Abstract] [Full Text] [Related]

  • 2. The effect of pramipexole on depressive symptoms in Parkinson's disease.
    Yasui N, Sekiguchi K, Hamaguchi H, Kanda F.
    Kobe J Med Sci; 2011 Feb 02; 56(5):E214-9. PubMed ID: 21937869
    [Abstract] [Full Text] [Related]

  • 3. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
    Barone P, Poewe W, Albrecht S, Debieuvre C, Massey D, Rascol O, Tolosa E, Weintraub D.
    Lancet Neurol; 2010 Jun 02; 9(6):573-80. PubMed ID: 20452823
    [Abstract] [Full Text] [Related]

  • 4. Effects of the dopamine agonist pramipexole on depression, anhedonia and motor functioning in Parkinson's disease.
    Lemke MR, Brecht HM, Koester J, Reichmann H.
    J Neurol Sci; 2006 Oct 25; 248(1-2):266-70. PubMed ID: 16814808
    [Abstract] [Full Text] [Related]

  • 5. Pramipexole, a nonergot dopamine agonist, is effective against rest tremor in intermediate to advanced Parkinson's disease.
    Künig G, Pogarell O, Möller JC, Delf M, Oertel WH.
    Clin Neuropharmacol; 1999 Oct 25; 22(5):301-5. PubMed ID: 10516884
    [Abstract] [Full Text] [Related]

  • 6. The effect of pramipexole on mood and motivational symptoms in Parkinson's disease: a meta-analysis of placebo-controlled studies.
    Leentjens AF, Koester J, Fruh B, Shephard DT, Barone P, Houben JJ.
    Clin Ther; 2009 Jan 25; 31(1):89-98. PubMed ID: 19243709
    [Abstract] [Full Text] [Related]

  • 7. The use of pramipexole, a novel dopamine (DA) agonist, in advanced Parkinson's disease.
    Molho ES, Factor SA, Weiner WJ, Sanchez-Ramos JR, Singer C, Shulman L, Brown D, Sheldon C.
    J Neural Transm Suppl; 1995 Jan 25; 45():225-30. PubMed ID: 8748629
    [Abstract] [Full Text] [Related]

  • 8. Double-blind, single-dose, cross-over study of the effects of pramipexole, pergolide, and placebo on rest tremor and UPDRS part III in Parkinson's disease.
    Navan P, Findley LJ, Jeffs JA, Pearce RK, Bain PG.
    Mov Disord; 2003 Feb 25; 18(2):176-80. PubMed ID: 12539211
    [Abstract] [Full Text] [Related]

  • 9. Conversion from dopamine agonists to pramipexole. An open-label trial in 227 patients with advanced Parkinson's disease.
    Linazasoro G, Spanish Dopamine Agonists Study Group.
    J Neurol; 2004 Mar 25; 251(3):335-9. PubMed ID: 15015015
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Anhedonia in Japanese patients with Parkinson's disease: analysis using the Snaith-Hamilton Pleasure Scale.
    Miura S, Kida H, Nakajima J, Noda K, Nagasato K, Ayabe M, Aizawa H, Hauser M, Taniwaki T.
    Clin Neurol Neurosurg; 2012 May 25; 114(4):352-5. PubMed ID: 22137783
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Dopamine and cognitive functioning in de novo subjects with Parkinson's disease: effects of pramipexole and pergolide on working memory.
    Costa A, Peppe A, Dell'Agnello G, Caltagirone C, Carlesimo GA.
    Neuropsychologia; 2009 Apr 25; 47(5):1374-81. PubMed ID: 19428401
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Randomized, double-blind, 3-month parallel study of the effects of pramipexole, pergolide, and placebo on Parkinsonian tremor.
    Navan P, Findley LJ, Jeffs JA, Pearce RK, Bain PG.
    Mov Disord; 2003 Nov 25; 18(11):1324-31. PubMed ID: 14639675
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Dopamine agonists in 6-pyruvoyl tetrahydropterin synthase deficiency.
    Porta F, Mussa A, Concolino D, Spada M, Ponzone A.
    Neurology; 2009 Aug 25; 73(8):633-7. PubMed ID: 19704083
    [Abstract] [Full Text] [Related]

  • 18. Effects of ropinirole on nonmotor symptoms of Parkinson disease: a prospective multicenter study.
    Rektorova I, Balaz M, Svatova J, Zarubova K, Honig I, Dostal V, Sedlackova S, Nestrasil I, Mastik J, Bares M, Veliskova J, Dusek L.
    Clin Neuropharmacol; 2008 Aug 25; 31(5):261-6. PubMed ID: 18836343
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Assessment of depression in Parkinson's disease: the contribution of somatic symptoms to the clinimetric performance of the Hamilton and Montgomery-Asberg rating scales.
    Reijnders JS, Lousberg R, Leentjens AF.
    J Psychosom Res; 2010 Jun 25; 68(6):561-5. PubMed ID: 20488273
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.